404
Participants
Start Date
March 31, 2006
Primary Completion Date
December 31, 2007
Study Completion Date
February 29, 2008
BG00002 (natalizumab)
Research Site, New York
Research Site, Great Neck
Research Site, Staten Island
Research Site, New York
Research Site, Albany
Research Site, Syracuse
Research Site, Buffalo
Research Site, Pittsburgh
Research Site, Pittsburgh
Research Site, Allentown
Research Site, Philadelphia
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Baltimore
Research Site, Charlottesville
Research Site, Raleigh
Research Site, Charlotte
Research Site, Atlanta
Research Site, Maitland
Research Site, Pompano Beach
Research Site, Miami
Research Site, Birmingham
Research Site, Nashville
Research Site, Memphis
Research Site, Cleveland
Research Site, Cincinnati
Research Site, Farmington Hills
Research Site, East Lansing
Research Site, Des Moines
Research Site, Milwaukee
Research Site, Fargo
Research Site, Arlington
Research Site, Northbrook
Research Site, Chicago
Research Site, Chicago
Research Site, Kansas City
Research Site, Little Rock
Research Site, Dallas
Research Site, Round Rock
Research Site, Colorado Springs
Research Site, Phoenix
Research Site, Scottsdale
Research Site, Albuquerque
Research Site, Los Angeles
Research Site, Redwood City
Research Site, San Francisco
Research Site, Berkeley
Research Site, Sacramento
Research Site, Portland
Research Site, New Haven
Research Site, Worcester
Research Site, Teaneck
Research Site, Burlington
Research Site, Vancouver
Research Site, Halifax
Research Site, Kingston
Research Site, London
Research Center, New York
Research Site, Ottawa
Research Site, Toronto
Research Site, Gatineau
Research Site, Greenfield Park
Research Site, Montreal
Lead Sponsor
Collaborators (1)
Elan Pharmaceuticals
INDUSTRY
Biogen
INDUSTRY